Innate Pharma's trifunctional NK cell engagers for multiple cancers

DISEASE CATEGORY: Cancer

INDICATION: Lung cancer; lymphoma; solid tumors

Innate Pharma S.A. showed that its trifunctional NK cell engager platform could be deployed against lymphoma, lung cancer and solid tumors. The

Read the full 308 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE